Safety and Immunogenicity of a Recombinant Parvovirus B19 Vaccine Formulated with MF59C.1 | Zendy

W. Ripley Ballou | Zendy; Jennifer L. Reed | Zendy; W. C. Noble | Zendy; Neal S. Young | Zendy; Scott Koenig | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Immunogenicity of a Recombinant Parvovirus B19 Vaccine Formulated with MF59C.1

Author(s) -

W. Ripley Ballou,

Jennifer L. Reed,

W. C. Noble,

Neal S. Young,

Scott Koenig

Publication year - 2003

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/368382

Subject(s) - immunogenicity , parvovirus , virology , parvoviridae , recombinant dna , medicine , immunology , biology , antibody , virus , genetics , gene

A recombinant human parvovirus B19 vaccine (MEDI-491; MedImmune) composed of the VP1 and VP2 capsid proteins and formulated with MF59C.1 adjuvant was evaluated in a randomized, double-blind, phase 1 trial. Parvovirus B19-seronegative adults (n=24) received either 2.5 or 25 microg MEDI-491 at 0, 1, and 6 months. MEDI-491 was safe and immunogenic. All volunteers developed neutralizing antibody titers that peaked after the third immunization and were sustained through study day 364.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research